BMEA
Biomea Fusion, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.01
+4.97%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +69.5%
- EBIT
- +49.6%
- EPS
- +83.6%
- Free cash flow
- +53.1%
- Operating cash flow
- +53.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -73.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- +55.8%
- EBIT
- +43.6%
- Net income
- +55.4%
- EPS
- +69.2%
- Free cash flow
- +41.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026